title: Atorvastatin in clinically-significant macular edema in diabetics with a normal lipid profile.
abstract: BACKGROUND
  Lipid-lowering drugs preserve vision and reduce the risk of hard exudates in clinically-significant macular edema(CSME) in diabetics with an abnormal lipid profile. But their role in reducing CSME in diabetics with a normal lipid profile is not yet known.
  
  
  OBJECTIVE
  To evaluate the role of atorvastatin in CSME in diabetics with a normal lipid profile.
  
  
  METHODS
  A prospective, randomized clinical trial was carried out. Thirty CSME patients with a normal lipid profile were randomly divided into Group A and B. Atorvastatin had been started in Group A four weeks prior to laser treatment. The main outcome measures were any improvement or deterioration in visual acuity and macular edema and hard exudates at six months follow-up.
  
  
  METHODS
  Both the groups were compared using unpaired t test for quantitative parameters and chi-square test for qualitative parameters. A p value of less than 0.05 was taken as significant.
  
  
  RESULTS
  Visual acuity, macular edema and hard exudates resolution was not significantly different in the two groups (P = 0.14, 0.62, 0.39 respectively).
  
  
  CONCLUSIONS
  Atorvastatin does not affect treatment outcome in CSME with a normal lipid profile over a short term follow-up.
authors.affiliation: Government Medical College Hospital, Chandigarh, India. subina_navya@yahoo.com
authors.forename: S
authors.initials: S
authors.lastname: Narang
authors.forename: S
authors.initials: S
authors.lastname: Sood
authors.forename: B
authors.initials: B
authors.lastname: Kaur
authors.forename: R
authors.initials: R
authors.lastname: Singh
authors.forename: A
authors.initials: A
authors.lastname: Mallik
authors.forename: J
authors.initials: J
authors.lastname: Kaur
mesh_terms: D000328:Adult; D000368:Aged; D000069059:Atorvastatin; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D008055:Lipids / Q000097:blood*; D008269:Macular Edema / Q000097:blood / Q000209:etiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011758:Pyrroles / Q000008:administration & dosage*; D013997:Time Factors; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D011758:Pyrroles; D000069059:Atorvastatin